Drug
Olopatadine
Important: Reactions below are the flagged terms from this drug’s
FAERS report history (min. 3 co-reports per term) — PRR/ROR indicate
disproportionality in spontaneous reporting, not causation.
Data from FDA FAERS via openFDA. Last recalculated: 2026-09-14.
| Reaction | Co-reports (a) | PRR | ROR | Signal | |
|---|---|---|---|---|---|
| 1 | Treatment Failure | 692 | 60.8 | 79.3 | signal |
| 2 | Seasonal Allergy | 28 | 14.2 | 14.3 | signal |
| 3 | Impaired Quality Of Life | 23 | 11.4 | 11.5 | signal |
| 4 | Obstructive Airways Disorder | 15 | 9.6 | 9.7 | signal |
| 5 | Eye Pruritus | 44 | 9.6 | 9.7 | signal |
| 6 | Renal Tubular Necrosis | 13 | 9.5 | 9.5 | signal |
| 7 | Eye Discharge | 12 | 8.4 | 8.4 | signal |
| 8 | Eye Inflammation | 11 | 8.3 | 8.4 | signal |
| 9 | Conjunctivitis | 19 | 7.4 | 7.4 | signal |
| 10 | Adrenal Insufficiency | 12 | 7.2 | 7.2 | signal |
| 11 | End Stage Renal Disease | 18 | 7.0 | 7.0 | signal |
| 12 | Cholecystectomy | 11 | 6.9 | 7.0 | signal |
| 13 | Dermatitis Atopic | 48 | 6.9 | 7.0 | signal |
| 14 | Immune System Disorder | 12 | 6.5 | 6.5 | signal |
| 15 | Blood Count Abnormal | 14 | 6.5 | 6.5 | signal |
| 16 | Ocular Hyperaemia | 41 | 6.3 | 6.4 | signal |
| 17 | Asthma | 97 | 6.2 | 6.4 | signal |
| 18 | Erythema Multiforme | 8 | 6.1 | 6.2 | signal |
| 19 | Dry Eye | 41 | 6.1 | 6.1 | signal |
| 20 | Lacrimation Increased | 24 | 5.7 | 5.8 | signal |
| 21 | Ear Discomfort | 8 | 5.6 | 5.6 | signal |
| 22 | Joint Dislocation | 8 | 5.4 | 5.4 | signal |
| 23 | Drug Eruption | 13 | 5.3 | 5.3 | signal |
| 24 | Eye Irritation | 39 | 5.0 | 5.1 | signal |
| 25 | Ankylosing Spondylitis | 9 | 4.9 | 5.0 | signal |
| 26 | Productive Cough | 31 | 4.7 | 4.7 | signal |
| 27 | Wheezing | 38 | 4.6 | 4.6 | signal |
| 28 | Pharyngitis | 8 | 4.6 | 4.6 | signal |
| 29 | Throat Tightness | 17 | 4.5 | 4.5 | signal |
| 30 | Nephropathy Toxic | 7 | 4.5 | 4.5 | signal |
| 31 | Infusion Site Pain | 8 | 4.5 | 4.5 | signal |
| 32 | Chronic Kidney Disease | 47 | 4.4 | 4.4 | signal |
| 33 | Pulmonary Mass | 9 | 4.3 | 4.3 | signal |
| 34 | Respiratory Disorder | 18 | 4.3 | 4.3 | signal |
| 35 | Sinusitis | 60 | 4.2 | 4.2 | signal |
| 36 | Hypersensitivity | 107 | 4.1 | 4.2 | signal |
| 37 | Serotonin Syndrome | 11 | 4.1 | 4.1 | signal |
| 38 | Cardiac Disorder | 52 | 4.0 | 4.0 | signal |
| 39 | Laryngitis | 6 | 4.0 | 4.0 | signal |
| 40 | Restless Legs Syndrome | 10 | 3.9 | 3.9 | signal |
| 41 | Brain Fog | 8 | 3.9 | 3.9 | signal |
| 42 | Intraocular Pressure Increased | 7 | 3.9 | 3.9 | signal |
| 43 | Increased Tendency To Bruise | 5 | 3.9 | 3.9 | signal |
| 44 | Sneezing | 12 | 3.8 | 3.9 | signal |
| 45 | Eye Infection | 6 | 3.8 | 3.8 | signal |
| 46 | Anhedonia | 14 | 3.8 | 3.8 | signal |
| 47 | Product Dose Omission In Error | 14 | 3.7 | 3.7 | signal |
| 48 | Angioedema | 23 | 3.7 | 3.7 | signal |
| 49 | Orthostatic Hypotension | 9 | 3.7 | 3.7 | signal |
| 50 | Dyspnoea Exertional | 19 | 3.6 | 3.6 | signal |
| 51 | Secretion Discharge | 6 | 3.5 | 3.5 | signal |
| 52 | Cyst | 6 | 3.5 | 3.5 | signal |
| 53 | Dermatitis | 10 | 3.5 | 3.5 | signal |
| 54 | Eczema | 24 | 3.4 | 3.4 | signal |
| 55 | Hereditary Angioedema | 5 | 3.4 | 3.4 | signal |
| 56 | Foot Fracture | 9 | 3.4 | 3.4 | signal |
| 57 | Cytokine Release Syndrome | 9 | 3.4 | 3.4 | signal |
| 58 | Bipolar Disorder | 5 | 3.3 | 3.3 | signal |
| 59 | Lip Swelling | 15 | 3.2 | 3.2 | signal |
| 60 | Rhinorrhoea | 29 | 3.2 | 3.2 | signal |
| 61 | Psoriatic Arthropathy | 18 | 3.2 | 3.2 | signal |
| 62 | Sinus Congestion | 6 | 3.2 | 3.2 | signal |
| 63 | Eye Pain | 24 | 3.1 | 3.1 | signal |
| 64 | Discomfort | 26 | 3.1 | 3.1 | signal |
| 65 | Thinking Abnormal | 8 | 3.1 | 3.1 | signal |
| 66 | Pharyngeal Swelling | 4 | 3.0 | 3.0 | no signal |
| 67 | Swollen Tongue | 13 | 3.0 | 3.0 | signal |
| 68 | Tendonitis | 6 | 2.8 | 2.8 | signal |
| 69 | Anaphylactic Reaction | 21 | 2.7 | 2.7 | signal |
| 70 | Transfusion | 4 | 2.7 | 2.7 | no signal |
| 71 | Full Blood Count Abnormal | 4 | 2.7 | 2.7 | no signal |
| 72 | Sleep Disorder Due To A General Medical Condition | 6 | 2.7 | 2.7 | signal |
| 73 | Therapeutic Response Shortened | 11 | 2.5 | 2.5 | signal |
| 74 | Macular Degeneration | 4 | 2.4 | 2.4 | no signal |
| 75 | Injection Site Irritation | 4 | 2.3 | 2.3 | no signal |
| 76 | Ovarian Cyst | 3 | 2.1 | 2.1 | no signal |
| 77 | Toxic Skin Eruption | 3 | 2.1 | 2.1 | no signal |
| 78 | Akathisia | 4 | 2.1 | 2.1 | no signal |
| 79 | Fistula | 3 | 1.9 | 1.9 | no signal |
| 80 | Bone Density Decreased | 8 | 1.8 | 1.8 | no signal |
| 81 | Incorrect Product Administration Duration | 5 | 1.8 | 1.8 | no signal |
| 82 | Hepatitis C | 3 | 1.8 | 1.8 | no signal |
| 83 | Mania | 4 | 1.7 | 1.7 | no signal |
| 84 | Application Site Irritation | 3 | 1.7 | 1.7 | no signal |
| 85 | Product Dose Omission | 15 | 1.6 | 1.6 | no signal |
| 86 | Psoriasis | 29 | 1.6 | 1.6 | no signal |
| 87 | Application Site Rash | 3 | 1.6 | 1.6 | no signal |
| 88 | Product Complaint | 5 | 1.4 | 1.4 | no signal |
| 89 | Injection Site Swelling | 15 | 1.4 | 1.4 | no signal |
| 90 | Exposure Via Skin Contact | 4 | 1.3 | 1.3 | no signal |
| 91 | Product Adhesion Issue | 6 | 1.2 | 1.2 | no signal |
| 92 | Application Site Pruritus | 3 | 0.9 | 0.9 | no signal |
| 93 | Injection Site Urticaria | 3 | 0.9 | 0.9 | no signal |
| 94 | Device Expulsion | 5 | 0.5 | 0.5 | no signal |
| 95 | Device Difficult To Use | 3 | 0.3 | 0.3 | no signal |